604 related articles for article (PubMed ID: 22323082)
21. The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity.
Myatt SS; Burchill SA
Oncogene; 2008 Feb; 27(7):985-96. PubMed ID: 17700534
[TBL] [Abstract][Full Text] [Related]
22. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H
Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784
[TBL] [Abstract][Full Text] [Related]
23. Ewing's sarcoma: general insights from a rare model.
Davis S; Meltzer PS
Cancer Cell; 2006 May; 9(5):331-2. PubMed ID: 16697953
[TBL] [Abstract][Full Text] [Related]
24. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.
Grohar PJ; Kim S; Rangel Rivera GO; Sen N; Haddock S; Harlow ML; Maloney NK; Zhu J; O'Neill M; Jones TL; Huppi K; Grandin M; Gehlhaus K; Klumpp-Thomas CA; Buehler E; Helman LJ; Martin SE; Caplen NJ
Cell Rep; 2016 Jan; 14(3):598-610. PubMed ID: 26776507
[TBL] [Abstract][Full Text] [Related]
25. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
26. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract][Full Text] [Related]
27. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
[TBL] [Abstract][Full Text] [Related]
28. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
[TBL] [Abstract][Full Text] [Related]
29. EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells.
Hu HM; Zielinska-Kwiatkowska A; Munro K; Wilcox J; Wu DY; Yang L; Chansky HA
J Orthop Res; 2008 Jun; 26(6):886-93. PubMed ID: 18271016
[TBL] [Abstract][Full Text] [Related]
30. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.
Ban J; Jug G; Mestdagh P; Schwentner R; Kauer M; Aryee DN; Schaefer KL; Nakatani F; Scotlandi K; Reiter M; Strunk D; Speleman F; Vandesompele J; Kovar H
Oncogene; 2011 May; 30(18):2173-80. PubMed ID: 21217773
[TBL] [Abstract][Full Text] [Related]
31. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
32. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.
Winter GE; Rix U; Lissat A; Stukalov A; Müllner MK; Bennett KL; Colinge J; Nijman SM; Kubicek S; Kovar H; Kontny U; Superti-Furga G
Mol Cancer Ther; 2011 Oct; 10(10):1846-56. PubMed ID: 21768330
[TBL] [Abstract][Full Text] [Related]
33. EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma.
Apfelbaum AA; Wu F; Hawkins AG; Magnuson B; Jiménez JA; Taylor SD; Wrenn ED; Waltner O; Pfaltzgraff ER; Song JY; Hall C; Wellik DM; Ljungman M; Furlan SN; Ryan RJH; Sarthy JF; Lawlor ER
Clin Cancer Res; 2022 Oct; 28(20):4466-4478. PubMed ID: 35653119
[TBL] [Abstract][Full Text] [Related]
34. AT-hook DNA-binding motif-containing protein one knockdown downregulates EWS-FLI1 transcriptional activity in Ewing's sarcoma cells.
Kitagawa T; Kobayashi D; Baron B; Okita H; Miyamoto T; Takai R; Paudel D; Ohta T; Asaoka Y; Tokunaga M; Nakagawa K; Furutani-Seiki M; Araki N; Kuramitsu Y; Kobayashi M
PLoS One; 2022; 17(10):e0269077. PubMed ID: 36194562
[TBL] [Abstract][Full Text] [Related]
35. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.
Herrero-Martín D; Osuna D; Ordóñez JL; Sevillano V; Martins AS; Mackintosh C; Campos M; Madoz-Gúrpide J; Otero-Motta AP; Caballero G; Amaral AT; Wai DH; Braun Y; Eisenacher M; Schaefer KL; Poremba C; de Alava E
Br J Cancer; 2009 Jul; 101(1):80-90. PubMed ID: 19491900
[TBL] [Abstract][Full Text] [Related]
36. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.
Owen LA; Kowalewski AA; Lessnick SL
PLoS One; 2008 Apr; 3(4):e1965. PubMed ID: 18414662
[TBL] [Abstract][Full Text] [Related]
37. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
38. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein.
Nakatani F; Tanaka K; Sakimura R; Matsumoto Y; Matsunobu T; Li X; Hanada M; Okada T; Iwamoto Y
J Biol Chem; 2003 Apr; 278(17):15105-15. PubMed ID: 12560328
[TBL] [Abstract][Full Text] [Related]
39. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
[TBL] [Abstract][Full Text] [Related]
40. Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem cells.
El Beaino M; Liu J; Wasylishen AR; Pourebrahim R; Migut A; Bessellieu BJ; Huang K; Lin PP
BMC Cancer; 2020 Jan; 20(1):3. PubMed ID: 31898537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
